Add to Favorites Newsroom RSS Share
New York, NY USA

Our News on Newswise

Norwalk Hospital and Memorial Sloan Kettering Launch Unique Cancer Care Collaboration

Norwalk Hospital and Memorial Sloan Kettering Cancer Center (MSK) today announced MSK Physicians at Norwalk Hospital, a new cancer care collaboration that will integrate MSK medical and radiation oncologists and care practices with the existing...
16-Oct-2017 6:00 AM EDT Add to Favorites

Cancer Immunologist Andrea Schietinger of Sloan Kettering Institute Honored with Prestigious NIH Director’s New Innovator Award

Cancer immunologist Andrea Schietinger, PhD, of the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering (MSK) has been honored with the prestigious National Institutes of Health (NIH) Director’s New Innovator Award.
5-Oct-2017 10:05 AM EDT Add to Favorites

m6A Enzymes Found to Be Central to the Development of AML

A team of researchers from Memorial Sloan Kettering Cancer Center (MSK) and Weill-Cornell Medical College have identified, for the first time, a new molecular pathway that is required for acute myeloid leukemia (AML) development. This work could...
28-Sep-2017 12:05 PM EDT Add to Favorites

Study Finds Rate of Mastectomies Decreases with Adoption of Breast Tumor Margin Guidelines: What This Means in the Overtreatment Debate for Breast Cancer

In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study...
1-Jun-2017 5:45 PM EDT Add to Favorites

Real-Time, Patient-Reported Symptom Monitoring Demonstrates an Overall Survival Benefit

Updated results of a clinical trial that launched in 2007 were presented today by Ethan Basch, MD, of Memorial Sloan Kettering Cancer Center (MSK) and UNC Lineberger Comprehensive Cancer Center, at the annual meeting of the American Society of...
2-Jun-2017 7:30 AM EDT Add to Favorites

Phase III Trial of PARP Inhibitor Shows First Evidence of Improved Outcomes in Breast Cancer

The first phase III trial of a PARP inhibitor used to treat breast cancer reported promising data at the annual meeting of the American Society of Clinical Oncology (ASCO). Mark Robson, MD, Clinic Director of the Clinical Genetics Service and...
1-Jun-2017 5:30 PM EDT Add to Favorites

Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from...
1-Jun-2017 5:35 PM EDT Add to Favorites

Novel Sequencing Approach Seeks to Detect Cancer’s Genomic Alterations

Findings from an early study evaluating a sophisticated new genomic-sequencing approach that analyzes cell-free DNA (cfDNA) in the blood of people with advanced cancer will help inform development of a future assay that could potentially detect...
1-Jun-2017 5:30 PM EDT Add to Favorites

Our YouTube Videos





Chat now!